chemotherapy dose intensity in patients with potentially curable malignancies should be considered a quality of care indicator in clinical oncology. (JNCCN 2009;7:99-108) Neutropenic complications, including febrile neutropenia resulting from myelosuppression, continue to represent the major dose-limiting toxicity of cancer.
Neutropenic complications, including febrile neutropenia resulting from myelosuppression, continue to represent the major dose-limiting toxicity of cancer. 1 Neutropenic complications are associated with substantial morbidity, mortality, and cost, as well as reductions in chemotherapy dose intensity. [1] [2] [3] [4] Reduced chemotherapy dose intensity may compromise progression-free and overall survival in responsive and potentially curable malignancies. 5, 6 Multiple randomized controlled clinical trials (RCTs) have shown that myeloid growth factors can decrease the incidence and severity of neutropenic events, including febrile neutropenia, resulting in fewer chemotherapy dose reductions or delays. 7 In clinical practice guidelines, several professional organizations recommend myeloid growth factors to reduce the risk for neutropenic complications and, when necessary, to sustain dose intensity in the curative setting.
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Chemotherapy-Induced Severe and Febrile Neutropenia
The risk for febrile neutropenia in patients undergoing cancer chemotherapy directly correlates with the severity and duration of neutropenia accompanying treatment-induced myelosuppression. 11 However, a systematic review of RCTs has shown that hematologic toxicity in patients undergoing chemotherapy is frequently underreported. 12 Investigators using data from health care claims have reported higher rates of serious adverse events associated with chemotherapy, most commonly because of neutropenic complications, than those reported in clinical trials. 13 The initial neutropenic episode in patients undergoing cancer chemotherapy occurs most frequently in the first cycle of chemotherapy. 1, 14, 15 The lower risk after cycle 1 appears to result from subsequent dose reductions and delays or the secondary use of a white blood cell growth factor. 16 In the absence of dose reductions or delays or the use of growth factor support, many patients experience multiple episodes of severe or febrile neutropenia. 16, 17 The greater risk for neutropenic complications among elderly cancer patients seems to be primarily because of the greater risk in the first cycle of treatment. 14, 15 Febrile neutropenia is still considered a medical emergency and, with few exceptions, requires hospitalization for immediate evaluation and the administration of empiric, broad-spectrum antibiotics. Inpatient mortality rates associated with hospitalization for febrile neutropenia in unselected patients range up to 10%. 2 Inpatient mortality in patients with febrile neutropenia is significantly associated with gram-negative and -positive sepsis, pneumonia, fungal infection, pulmonary embolism, hypotension, and comorbidities, including cardiac, cerebrovascular, renal, and liver diseases. 2 Furthermore, the economic impact of hospitalization with febrile neutropenia approaches $20,000 or more per hospitalization. 2 In addition to the direct medical costs associated with the diagnosis and treatment of febrile neutropenia, nonmedical, indirect, and out-of-pocket expenses represent major additional expenses for patients and families. 18, 19 Nevertheless, the impact of myelosuppression and associated neutropenia on the delivery of full dose intensity chemotherapy in the curative setting may represent the most serious consequence of severe or febrile neutropenia. 20 
Clinical Importance of Sustaining Chemotherapy Dose Intensity
Relative dose intensity (RDI) represents the ratio of the dose intensity actually delivered, to the standard dose intensity for a chemotherapy regimen generally established in large phase III efficacy clinical trials. By convention, dose intensity represents the dose given per unit body surface area (BSA) per unit time (e.g., mg/m 2 /wk). 21 The impact of chemotherapy dose and dose intensity on malignant disease has been studied in various settings. In vitro, drug concentration in culture for many chemotherapeutic agents correlates directly with tumor cell kill and inversely with the rate of tumor growth. 22 A dose-response relationship has been shown in vivo in multiple animal tumor models with reductions in dose intensity consistently associated with lower response rates, as well as less potential for cure. In a study by Skipper., 23 as little as a 20% dose reduction resulted in a reduction in cure rates by 50% or more. In humans, abundant clinical data supporting a dose-response relationship for chemotherapy in cancer patients has been demonstrated in both the early stage and advanced disease settings. In patients with metastatic disease, chemotherapy dose intensity is consistently associated with increased rates of complete and partial response, as well as progression-free survival. 24, 25 In patients with early-stage cancers, the relationship between reductions in delivered dose intensity and poorer outcome has been shown in retrospective studies and several prospective clinical trials.
Retrospective Studies
Retrospective analyses of RCTs suggest a strong relationship between reductions in chemotherapy dose intensity and poorer disease-free and overall survival. In an early study by the National Cancer Institute in Milan, patients with lymph node-negative early-stage breast cancer randomized to undergo systemic adjuvant chemotherapy with CMF (cyclophosphamide, methotrexate, 5-fluorouracil) who received more than 85% of planned dose intensity were found to have better disease-free and overall survival than those who received lower dose intensity in retrospective analysis. 5 As shown in Fig. 1 , patients receiving less than 65% of standard dose intensity experienced survival virtually identical to untreated controls, whereas those receiving less reductions of dose intensity retained some benefit, albeit reduced.
A recent retrospective analysis of 4 separate randomized controlled trials in early-stage breast cancer suggests that the survival impact of reduced dose intensity is primarily apparent in patients with hormone receptor-negative disease. 26 These findings are consistent with studies showing a significant impact of delays in the initiation of adjuvant systemic chemotherapy on survival in elderly women with early-stage breast cancer. 27 Similarly, patients with aggressive non-Hodgkin's lymphoma (NHL) who received cyclophosphamide, doxorubicin, vincristine, prednisone (CHOP) with an RDI greater than 70% experienced better 5-year survival compared with those receiving 70% or less. 28 Likewise, Lepage et al. 29 found that patients with NHL receiving a planned dose intensity of 70% or greater had significantly longer survival. Kwak et al. 30 reported that patients with diffuse large-cell NHL receiving 75% or less of standard chemotherapy dose intensity experienced significantly shorter survival. However, despite greater overall risk for disease progression after initial treatment, Lee et al. 31 reported no significant improvement in overall survival with full dose-intensity chemotherapy among older patients with lymphoma.
Myelosuppression as a Surrogate for Chemotherapy Dose Intensity
In various malignancies, several investigators have shown a significant association between myelosuppression, including leukopenia and neutropenia during chemotherapy and improved survival. Myelosuppression is considered a surrogate for chemotherapy dose intensity, suggesting a strong association between dose intensity and clinical efficacy.
In a study of 484 women undergoing adjuvant chemotherapy for early-stage breast cancer, Mayers et al. 32 reported that those experiencing myelosuppression during treatment experienced significantly improved survival at 15 years after adjusting for stage, hormone receptor status, and type of treatment (hazard ratio, 0.77; 95% CI, 0.59-1.00; Fig. 2 ). 32 Likewise, Di Maio et al. 33 reported that patients with lung cancer experiencing neutropenia during chemotherapy have significantly longer survival based on a combined analysis from 3 randomized trials.
Although these studies are limited by their retrospective design, the authors of the above studies conclude that the favorable results associated with neutropenia are related to its role as a surrogate indicator for chemotherapy dose intensity. A recent prospective observational study of nearly 2500 unselected patients with cancer, including breast, colorectal, ovarian, lung carcinomas, and malignant lymphoma, followed-up patients through the initial course of treatment. 1 Patients with early-stage (1-3) disease experiencing one or more episodes of severe neutropenia during systemic chemotherapy experienced significantly better progression-free and overall survival than those not experiencing severe neutropenia (Fig. 3) .
Prospective Randomized Controlled Trials
The updated Oxford overview of RCTs comparing adjuvant chemotherapy with no chemotherapy in earlystage breast cancer reported significant reductions in risk for recurrence and breast cancer and all-cause mortality at 15 years. 34 When compared with women who had untreated breast cancer, adjuvant chemotherapy resulted in reductions in mortality rates by 38% in those younger than 50 years and 20% in women aged 50 years or older. Therefore, clinical efficacy is lost between the dose intensity actually delivered to chemotherapy patients in the trials and no treatment, as received in the control arms.
Unfortunately, RCTs in oncology have often failed to report important information concerning the RDI of chemotherapy received by patients in the trial. 12 In addition, direct randomization to reduced chemotherapy dose-intensity schedules has only been conducted in a few RCTs. Women with lymph node-positive earlystage breast cancer were randomized in CALGB 8541 to receive 3 different dose intensities of cyclophosphamide, doxorubicin, and 5-fluorouracil (Fig. 4) . 6 Over a median of 9 years, patients in the low dose-intensity arm experienced worse disease-free and overall survival than in the moderate and full dose intensity arms.
More recently, the French Adjuvant Breast Cancer Group reported that full-dose fluorouracil, epirubicin, and cyclophosphamide (FEC) resulted in improved 10-year disease-free and overall survival compared with reduced dose-intensity FEC. 35 In addition, a randomized phase II study in older patients with small cell lung cancer observed that full-dose platinum and etoposide resulted in one-year survivals of 39% compared to 18% with reduced dose intensity. 36 In the recent prospective observational study of unselected patients with early-stage disease discussed earlier, an RDI greater than 85% was associated with significantly better early progression-free and overall survival than those receiving an RDI of 85% or less or a nonstandard chemotherapy regimen (Fig. 5) .
The planning of additional RCTs to further address this issue is limited by the ethical concerns around randomization to less-intensive and potentially less effective therapy, particularly in the curative setting. However, the number of patients and duration of follow-up required in each arm of RCTs designed to study the impact of a 10% to 25% reduction in RDI on survival is substantial. 
Dose-Dense and Dose Escalation Studies
Several clinical trials of escalating drug doses have shown inconsistent results, generally providing little clinical benefit while considerably increasing toxicity. Early modeling studies followed by preliminary clinical trials have generated considerable interest in delivering conventional chemotherapy doses at more frequent intervals. 37 Tumor cell kill with chemotherapy increases growth rate of the remaining cells, causing greater tumor cell kill by many cytotoxic agents.
Norton and Simon 37 developed mathematical models predicting greater tumor cell kill and slower tumor regrowth between cycles with compression of the schedule of chemotherapeutic agents. These dosedense schedules increase the RDI of chemotherapy but must generally be supported by the administration of myeloid growth factors to enable the more frequent delivery of myelosuppressive agents. Prospective RCTs of dose-dense schedules have reported improved survival in early-stage breast cancer and NHL. 38, 39 The comparative efficacy of dose-dense scheduling and the introduction of new active agents with novel mechanisms of action has not been fully clarified. Nevertheless, the available data add further support to the contention that dose intensity is an important clinical consideration. 
Disparities in Chemotherapy Dose Intensity in Clinical Practice
Although most oncologists find the evidence convincing for maintaining chemotherapy dose intensity discussed earlier, many studies suggest that considerable disparity continues to exist in the delivery of cancer treatment, including reductions in the delivery of chemotherapy dose intensity. 20 Chu and DeVita 22 concluded that these reductions in chemotherapy dose intensity in patients with responsive malignancies represent a major reason for treatment failure in both early and advanced disease settings.
Practice Pattern Surveys of Delivered Chemotherapy Dose Intensity
In addition to frequent protocol-mandated reductions in chemotherapy dose intensity in clinical trials, several recent practice pattern studies have reported that patients with treatable and potentially curable malignancies are often undertreated.
3,4,9,40-44 A retrospective study of nearly 20,000 women with early-stage breast cancer treated throughout the United States reported that more than half received less than 85% of standard dose intensity. 3 Planned reductions in dose intensity from the start of treatment were observed in two thirds of patients, whereas unplanned reductions were generally related to treatment toxicity. Another retrospective U.S. study of 4500 patients with aggressive NHL receiving CHOP or CHOP-like chemotherapy showed that nearly half received less than 85% of standard dose intensity based on NCCN guidelines. 4 Disparities identified in these studies included greater reductions in delivered dose intensity in older patients and those who were overweight or obese. 3, 4 In a more recent survey, approximately 30% of women with early-stage breast cancer received RDIs less than 85%. 42 Significant predictors of reduced dose intensity, among others, included older age, BSA greater than 2 m 2 , and the number and type of comorbidities.
The results of these studies are consistent with a recent study that surveyed oncologists throughout Australia and found considerable variation in chemotherapy dosing strategies, concluding that a substantial number of patients with early-stage disease are being undertreated. 19, 44 Reductions in Chemotherapy Dose Intensity in Overweight and Obese Patients: At least half of the reductions in chemotherapy dose intensity observed in practice surveys are planned from the beginning of treatment, most commonly because of the downward dose adjustment in overweight and obese patients. Such dose adjustments may result from the use of either ideal or adjusted body weight rather than actual weight and the capping of BSA or the glomerular filtration rate often utilized in total dose calculations for common agents. Multiple studies have shown that reductions in standard dose intensity are frequent in overweight and obese patients (Fig. 6) . 3, 26, 41, 45 However, multiple authors have reported data suggesting that reductions in chemotherapy dose intensity in overweight patients are not only unwarranted but may compromise long-term outcomes, perhaps partly explaining the worsening survival with increasing obesity. 41, 46 In an important study by CALGB, obese patients with early-stage breast cancer who, nevertheless, received full dose intensity had no greater risk for toxicity and experienced recurrence rates comparable to patients of healthy weight, whereas those undergoing reduced chemotherapy dose intensity experienced a greater risk for recurrence. 46 Recent pharmacokinetic studies have clearly shown that serum levels of many chemotherapeutic agents are suboptimal when dosed on the basis of adjusted weight suggesting that actual, rather than ideal, body weight should be used in dose calculations. 47, 48 Reductions in Chemotherapy Dose Intensity Related to Demographic and Socioeconomic Considerations: Studies have also shown that planned reductions in chemotherapy dose intensity are also associated with older age, race, and socioeconomic factors. 3, 14, 42, 43, 49 These factors and patient and physician education may create barriers to the optimal delivery of effective treatment in patients with curable malignancies. 19, 44, 50, 51 Cancer is largely a disease of aging, and the treatment of cancer in elderly patients should be cognizant of both limited bone marrow reserves in older patients and any associated comorbidities. 52 With modern supportive care, however, it has been shown that most elderly cancer patients can both tolerate and benefit from standard chemotherapy regimens. 7, 10, 43 In the retrospective study of women undergoing adjuvant breast cancer chemotherapy discussed earlier, the proportion of women receiving less than 85% of standard chemotherapy RDI increased to 67% among those aged 65 years and older (P < .001). 3 Similarly, in the study of patients with NHL, the proportion of patients receiving less than 85% of standard RDI was 60% in those aged 60 years or older compared with 44% in younger patients. 4 Reduced dose intensity may also result from patient refusal or noncompliance and limited access to care based on geography, education, and costs. Unplanned Reductions in Chemotherapy Dose Intensity: Myelosuppression is the most common reason for reduced dose intensity during a course of chemotherapy. 53 Treatment delays often occur as a result of inadequate neutrophil recovery, whereas chemotherapy dose reductions are most frequently the consequence of severe or febrile neutropenia. Dose reductions and treatment delays may also result from other hematologic toxicities, including anemia, thrombocytopenia, and nonhematologic toxicities, such as nausea and vomiting, mucositis, and renal dysfunction. 20 Ultimately, these toxicities may result in modifications in the chemotherapy regimen or early cessation. Clearly, reduced dose intensity is sometimes necessary in very elderly, frail, or debilitated patients. These modifications may also sometimes be appropriate for patients with advanced disease when the focus is on the quality of life.
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Myeloid Growth Factors to Sustain Chemotherapy Dose Intensity
Myeloid growth factors have been shown to sustain full dose intensity in patients undergoing conventional chemotherapy for potentially curable malignancies. 7, 54 The most recent overview identified 10 RCTs of primary granulocyte-colony stimulating factor (G-CSF) prophylaxis in patients undergoing chemotherapy for solid tumors or malignant lymphoma. The mean and median RDIs reported in control subjects for these studies were 86.7% and 88.5%, respectively, whereas they were 95.1% and 95.5% among patients randomized to receive G-CSF. 7 The differences in RDI between treatment groups ranged from 2.8% to 20.0%, with average differences of 8.4% favoring patients treated with G-CSF (P = .001). Of 10 studies, 6 reported average RDI below 90% in control patients compared with 0 in the 10 G-CSF treatment arms (Figure 7) .
Among elderly patients with aggressive NHL receiving CHOP chemotherapy, RCTs have shown that those receiving G-CSF experienced significantly greater chemotherapy RDI. 55, 56 In a recent meta-analysis, RCTs restricted to elderly patients undergoing conventional chemotherapy showed significant reductions in the risk for febrile neutropenia with primary G-CSF prophylaxis (RR, 0.68; 95% CI, 0.53-0.87), with trends toward reduced infection-related (RR, 0.52; 95% CI, 0.27-1.02) and all-cause early mortality (RR, 0.51; 95% CI, 0.20-1.28). 7 Finally, prospective studies of chemotherapy using dose-dense schedules requiring support with a myeloid growth factor have shown potential for increasing the delivery of chemotherapy dose intensity with little or no increase in toxicity. 38, 39 Although early results are encouraging, longer follow-up is required to fully define how these dose-dense schedules impact long-term outcomes. Current clinical practice guidelines support using myeloid growth factors to sustain dose intensity or provide dose-dense chemotherapy where indicated.
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Current and Future Directions
Improving the quality of patient care is an important goal for all oncologists. The Institute of Medicine report on Ensuring Quality Cancer Care published in 1999 prompted several initiatives to improve the quality of cancer patient management. 57 In response to this report, the National Initiative on Cancer Care Quality was initiated, which concluded that quality of oncology care needed to be improved in several areas, including management of treatment-related side effects, optimal chemotherapy dosing, and improved documentation of important clinical information. 58 Strong evidence shows that patients with responsive and potentially curable malignancies benefit from the delivery of full-dose cancer chemotherapy. Reducing the delivery of full chemotherapy dose intensity through treatment delays, dose reduction, or early termination of cancer treatment may increase the risk for recurrence and death from cancer. Delivery of full chemotherapy dose intensity should be the goal in all patients with potentially curable malignancies, representing an important quality measure allowing practices to benchmark their experience with that of other practices. 59, 60 Although more recent clinical trial protocols appear to require fewer reductions in chemotherapy dose intensity, the majority of protocols either mandate or fail to specify required dose intensity modifications. 61 Earlier studies with mandated BSA capping demonstrated a significant increase in disease-specific mortality among very obese patients with colorectal cancer. 62 On the other hand, more recent trials in this setting without mandated BSA capping demonstrate no increase in disease-specific mortality based on weight. 63 There is clearly a need for improved awareness of these data and greater consistently in chemotherapy dosing across cancer clinical trials. For BSA-based dosing in the overweight and obese patient, arbitrary BSA limits should be avoided while measured creatinine clearances should be used to guide area under the curve-based dosing in such patients.
Data supporting the importance of delivered chemotherapy dose intensity to long-term outcomes, including cancer patient survival, are compelling. Although further controlled clinical trials are needed on the role of dose escalation and dose-dense strategies, oncologists should seriously consider the strong evidence from both preclinical and clinical studies supporting the importance to cancer patient outcomes of sustaining full dose intensity. Along with other ASCO/NCCN quality measures already in place, the delivery of full-dose chemotherapy where indicated should be considered an important process measure of quality cancer care.
